349 related articles for article (PubMed ID: 27496093)
1. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
2. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
3. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
4. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
[TBL] [Abstract][Full Text] [Related]
6. The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
Hjortkjær M; Malik Aagaard Jørgensen M; Waldstrøm M; Ørnskov D; Søgaard-Andersen E; Jakobsen A; Dahl-Steffensen K
Int J Gynecol Cancer; 2019 Jan; 29(1):166-173. PubMed ID: 30640700
[TBL] [Abstract][Full Text] [Related]
7. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.
Weiderpass E; Tyczynski JE
Mol Diagn Ther; 2015 Dec; 19(6):351-64. PubMed ID: 26476542
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
10. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA repair: the genome as a potential biomarker.
Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
[TBL] [Abstract][Full Text] [Related]
14. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
15. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
Hussein YR; Ducie JA; Arnold AG; Kauff ND; Vargas-Alvarez HA; Sala E; Levine DA; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):404-9. PubMed ID: 26574845
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
[TBL] [Abstract][Full Text] [Related]
17. Cytology material is equivalent to tumor tissue in determining mutations of BRCA 1/2 genes in patients with tubo-ovarian high grade serous carcinoma.
Gornjec A; Novakovic S; Stegel V; Hocevar M; Pohar Marinsek Z; Gazic B; Krajc M; Skof E
BMC Cancer; 2019 Apr; 19(1):296. PubMed ID: 30940100
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population.
Sekine M; Nagata H; Tsuji S; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Tanaka K;
Clin Cancer Res; 2001 Oct; 7(10):3144-50. PubMed ID: 11595708
[TBL] [Abstract][Full Text] [Related]
19. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Soslow RA; Han G; Park KJ; Garg K; Olvera N; Spriggs DR; Kauff ND; Levine DA
Mod Pathol; 2012 Apr; 25(4):625-36. PubMed ID: 22193042
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]